Strategic Report on Adalimumab, Infliximab and Etanercept Biosimilars Market: Growth Opportunities and Emerging Challenges
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Does the Forecast Indicate for the Adalimumab, Infliximab and Etanercept Biosimilars Market From 2025 to 2029?
The market size of adalimumab, infliximab, and etanercept biosimilars has experienced swift expansion in the past few years. The market value is anticipated to rise from $4.37 billion in 2024 to $4.96 billion in 2025, showing a compound annual growth rate (CAGR) of 13.6%. Factors contributing to growth during the historical period include an uptick in healthcare spending, regulatory adjustments, government strategies, and escalating healthcare expenses.
The market size for adalimumab, infliximab and etanercept biosimilars is anticipated to witness a substantial surge in the upcoming years. The market is predicted to reach “$7.34 billion by 2029, with a compound annual growth rate (CAGR) of 10.3%. Factors such as growing healthcare costs, an aging demographic, and improved healthcare access are anticipated to fuel this growth. Key trends during the projected period will comprise of initiatives towards new product launches, increased focus on mergers and acquisitions, strategic partnerships, and enhanced investment opportunities.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp
What Elements Are Contributing To Growth In The Adalimumab, Infliximab and Etanercept Biosimilars Market?
The accessibility of biosimilars in the adalimumab, infliximab, and etanercept biosimilars market has been driven by the expiration of patents on branded drugs. This includes in the United States, where Inflectra, produced by Hospira (owned by Pfizer Inc.), was sanctioned by the FDA for treating several autoimmune diseases, such as rheumatoid arthritis, adult ulcerative colitis, and plaque psoriasis. This followed the end of the patent on the branded drug, Remicade. In a similar case, the European Commission approved Benepali, a biosimilar of Amgen’s Enbrel, once its patent concluded in the EU. Following the termination of Humira’s patent, its biosimilars have been brought to market, with the FDA recently approving Hulio, Humira’s sixth biosimilar. Therefore, the conclusion of patents for branded biologic drugs like Humira, Enbrel, and Remicade is stimulating demand in the adalimumab, infliximab, and etanercept biosimilars market.
The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented –
1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications
Subsegments:
1) By Adalimumab Biosimilars: Amjevita (Amgen), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), Others
2) By Infliximab Biosimilars: Inflectra (Pfizer), Remsima (Celltrion), Ixifi (Pfizer), Others
3) By Cipleumab: Cipleumab Biosimilars, Other Biosimilars in Development
What Long-Term Trends Are Likely To Affect The Adalimumab, Infliximab and Etanercept Biosimilars Market?
Leading firms engaged in the adalimumab, infliximab, and etanercept biosimilars market are concentrating on the creation of novel products, such as citrate-free adalimumab, in order to offer dependable services to their clients. Citrate-free adalimumab is an iteration of the biological drug adalimumab that does not include citrate. For example, in December 2022, Fresenius Kabi, a German enterprise specializing in the manufacturing of medications and technologies related to infusion, transfusion, and clinical nutrition, received FDA approval for their biosimilar product, Idacio (adalimumab), for the control of persistent autoimmune disorders, permitting all authorized uses of the standard product. This product was developed using enhanced analytical methods for the treatment of multiple chronic diseases.
Who Are The Key Contributors To Growth In The Adalimumab, Infliximab and Etanercept Biosimilars Market?
Major companies operating in the adalimumab, infliximab and etanercept biosimilars market include Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions, Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad, Roche, Bristol-Myers Squibb, Celon Pharma, SynBio, Ache, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Mylan, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty) Ltd
Which Region Is Projected To Lead The Adalimumab, Infliximab and Etanercept Biosimilars Market By 2025?
North America was the largest region in the adalimumab, infliximab, and etanercept biosimilars market in 2024. The regions covered in the adalimumab, infliximab, and etanercept biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=3473&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
